Search results (1345)
« Back to PublicationsReal-world data: the incidence, diagnosis, and management outcomes of patients with immunotherapy-related colitis in two tertiary centres
Cheung V. et al, (2019), JOURNAL OF CROHNS & COLITIS, 13, S137 - S138
The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
Butt NM. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 54 - 55
Whole genome sequencing for the investigation of rare anaemias: Challenges and real-world outcomes
Brierley C. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 115 - 116
Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly Diffuse large B cell lymphoma (DLBCL) patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Eyre TA. et al, (2019), Journal of internal medicine
BRN2 suppresses apoptosis, reprograms DNA damage repair and is associated with a high somatic mutation burden in melanoma
GODING C. et al, (2019), Genes and Development
The Use of Digital Pathology and Image Analysis in Clinical Trials
Pell R. et al, (2019), The Journal of Pathology: Clinical Research
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D. et al, (2019), JAMA oncology, 5, e184475 - e184475
Age-Related Changes in Tumoral Angiogenesis Drive Melanoma Metastasis and Response to Targeted Therapy
Ecker B. et al, (2019), ANNALS OF SURGICAL ONCOLOGY, 26, S38 - S39
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Eyre TA. et al, (2019), Haematologica, 104, e68 - e71
Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Brierley CK. et al, (2019), Br J Haematol, 184, 547 - 557
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.
Gupta V. et al, (2019), Biol Blood Marrow Transplant, 25, 256 - 264
Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.
Gray MD. et al, (2019), Radiology, 181445 - 181445
Planning and Delivery of Ultrasound- Mediated Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial
MIDDLETON MR. et al, (2019), Radiology
Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery.
Findlay JM. et al, (2019), European radiology
The Circulating Transcriptome as a Source of Biomarkers for Melanoma.
Solé C. et al, (2019), Cancers (Basel), 11
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
Plummer ER. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.
McMullin MFF. et al, (2019), British journal of haematology, 184, 161 - 175
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA. et al, (2019), Cancer, 125, 99 - 108
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
Banerji U. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy.
Gilmore E. et al, (2019), J Oncol, 2019